


## Utibapril

Cat. No.:	HY-101681
CAS No.:	109683-61-6
Molecular Formula:	C <sub>22</sub> H <sub>31</sub> N <sub>3</sub> O <sub>5</sub> S
Molecular Weight:	449.56
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities.
In Vivo	Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 µg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 µg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril <sup>[1]</sup> . FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. *J Cardiovasc Pharmacol.* 1997 May;29(5):684-91.

[2]. Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. *Br J Pharmacol.* 1990 May;100(1):90-4.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA